Steel Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Steel Therapeutics is a novel pharmaceutical company with a unique strategy of taking established, efficacious therapies from the compounding pharmacy space and developing them into FDA-approved products with optimized delivery. Its first candidate, Fizurex™, is a disposable wipe formulation of nifedipine and lidocaine for anal fissures, aiming to replace compounded creams. The founding team combines deep expertise in pharmacy compounding, pharmaceutical commercialization, medical device regulation, and finance, positioning the company to bridge a significant gap between unregulated compounding and standardized, scalable pharmaceutical products.

HematologyOncology

Technology Platform

A development and regulatory strategy focused on optimizing the formulation and delivery of proven drug combinations from the compounding pharmacy space to create standardized, FDA-approved products.

Opportunities

The company addresses a large, underserved market by transforming niche compounded therapies into broadly accessible, FDA-approved products.

Its capital-efficient model of developing known drug combinations reduces early-stage discovery risk and can lead to faster development timelines compared to novel drug discovery.

Risk Factors

Key risks include the significant regulatory challenge of obtaining FDA approval for a new formulation of old drugs, potential difficulties in securing insurance reimbursement against low-cost generic or compounded alternatives, and the company's heavy reliance on its single, early-stage lead candidate.

Competitive Landscape

For Fizurex, competition includes over-the-counter creams, prescription nitroglycerin/other topical agents, and the existing compounding pharmacy market. More broadly, the company's model is novel, so direct competitors are few, but it may face future competition from larger pharmaceutical companies if the strategy proves successful.

More companies in Small Molecule Drugs →More companies in United States →